Goldman Sachs: Oral weight loss drugs will be one of the most promising new medications in recent years!

Goldman Sachs predicts that by 2030, oral weight loss drugs will account for 24% of the total weight loss drug market, and Eli Lilly and Co will lead this segment with its orforglipron. Next, pay close attention to the third-quarter results of the ATTAIN-1 trial announced by Eli Lilly, which will be the first reading of orforglipron in the field of obesity and the most important next catalyst for the oral obesity drug market.

wallstreetcn20:47 ET

Here's the Major Earnings Before the Open Tomorrow

Seeking Alpha18:00 ET

SA Analyst Downgrades: TSLA, AAPL, T, PG, HPE, GILD, LRCX, ARCC

Seeking Alpha14:26 ET

9 Health Care Stocks Whale Activity In Today's Session

Benzinga13:35 ET

What's Going On With Verizon (VZ) Stock During Monday's Session?

Benzinga13:07 ET

Pfizer Q1 Earnings Preview: Wall Street Expects Y-o-y Declines in Both EPS and Revenue

Seeking Alpha12:49 ET